ValuEngine lowered shares of Fluidigm Corporation (NASDAQ:FLDM) from a sell rating to a strong sell rating in a research note published on Thursday, November 9th.
Fluidigm Corporation (NASDAQ FLDM) traded up $0.18 during mid-day trading on Thursday, hitting $5.37. 133,700 shares of the company’s stock were exchanged, compared to its average volume of 258,845. Fluidigm Corporation has a 12-month low of $2.52 and a 12-month high of $8.69. The company has a debt-to-equity ratio of 5.00, a quick ratio of 2.46 and a current ratio of 3.02.
TRADEMARK VIOLATION WARNING: “Fluidigm Corporation (FLDM) Downgraded by ValuEngine to Strong Sell” was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/fluidigm-corporation-fldm-downgraded-by-valuengine/1771544.html.
In other news, insider Levin Capital Strategies, L.P. acquired 95,843 shares of the firm’s stock in a transaction on Tuesday, October 10th. The shares were purchased at an average price of $4.57 per share, for a total transaction of $438,002.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 498,413 shares of company stock worth $2,386,134 in the last 90 days. Corporate insiders own 4.70% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Neuberger Berman Group LLC boosted its stake in shares of Fluidigm Corporation by 181.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 5,213,481 shares of the medical research company’s stock valued at $26,276,000 after purchasing an additional 3,362,100 shares in the last quarter. Group One Trading L.P. boosted its stake in shares of Fluidigm Corporation by 336.9% during the 3rd quarter. Group One Trading L.P. now owns 23,155 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 17,855 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Fluidigm Corporation by 8.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 305,161 shares of the medical research company’s stock valued at $1,538,000 after purchasing an additional 22,700 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Fluidigm Corporation during the 3rd quarter valued at about $123,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Fluidigm Corporation by 46.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,447,491 shares of the medical research company’s stock valued at $17,370,000 after purchasing an additional 1,099,072 shares in the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with our FREE daily email newsletter.